These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1026 related items for PubMed ID: 19460503

  • 1. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 May; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 4. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH.
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [Abstract] [Full Text] [Related]

  • 5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 6. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 7. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
    Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW.
    Transplant Proc; 2016 Jul; 48(6):2006-10. PubMed ID: 27569936
    [Abstract] [Full Text] [Related]

  • 8. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.
    Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831
    [Abstract] [Full Text] [Related]

  • 11. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.
    Transplant Proc; 2013 Apr 27; 45(6):2387-92. PubMed ID: 23953553
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM.
    Transplantation; 2010 Jul 15; 90(1):31-7. PubMed ID: 20517177
    [Abstract] [Full Text] [Related]

  • 15. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.
    Transplantation; 1997 Dec 27; 64(12):1755-60. PubMed ID: 9422416
    [Abstract] [Full Text] [Related]

  • 16. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M.
    J Nephrol; 2011 Dec 27; 24(5):613-8. PubMed ID: 21240873
    [Abstract] [Full Text] [Related]

  • 17. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.
    Clin J Am Soc Nephrol; 2012 Mar 27; 7(3):504-12. PubMed ID: 22282478
    [Abstract] [Full Text] [Related]

  • 18. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ, Yang HC, Holman MJ, Ahsan N.
    J Transpl Coord; 1999 Jun 27; 9(2):114-8. PubMed ID: 10703393
    [Abstract] [Full Text] [Related]

  • 19. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F.
    Trials; 2016 Feb 17; 17():92. PubMed ID: 26888217
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan 17; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.